A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

por Türeci, O, Sahin, U, Schulze-Bergkamen, H, Zvirbule, Z, Lordick, F, Koeberle, D, Thuss-Patience, P, Ettrich, T, Arnold, D, Bassermann, F, Al-Batran, S E, Wiechen, K, Dhaene, K, Maurus, D, Gold, M, Huber, C, Krivoshik, A, Arozullah, A, Park, J W, Schuler, M
Publicado 2019